Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged " 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.
Abstract
Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged " 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.
참고문헌 (18)
- DeVita VT Jr, "DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 10th ed." (2014), Lippincott Williams & Wilkins
- Clark MA, "Soft-tissue sarcomas in adults", N Engl J Med, 353, pp.701~711 (2005)[DOI]
- Santoro A, "Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group", J Clin Oncol, 13, pp.1537~1545 (1995)[DOI]
- Elias A, "Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy", J Clin Oncol, 7, pp.1208~1216 (1989)[DOI]
- Antman KH, "Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma", J Clin Oncol, 7, pp.126~131 (1989)[DOI]
- [URL]
- ESMO, "European Sarcoma Network Working Group", Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2014, pp.25(Suppl 3), iii102~iii12
- Sheng JY, "Systemic therapy for advanced soft tissue sarcoma", Surg Clin North Am, 96, pp.1141~1156 (2016)[DOI]
- Ratan R, "Chemotherapy for soft tissue sarcoma", Cancer, 122, pp.2952~2960 (2016)[DOI]
- Colosia A, "A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma", Sarcoma, 2016, pp.3597609~ (2016)
- Bay JO, "Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis", Int J Cancer, 119, pp.706~711 (2006)[DOI]
- Maki RG, "Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002", J Clin Oncol, 25, pp.2755~2763 (2007)[DOI]
- Kaya AO, "Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma", Asian Pac J Cancer Prev, 13, pp.463~467 (2012)[DOI]
- Pink D, "Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis", Oncology, 87, pp.95~103 (2014)[DOI]
- Rapkin L, "Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas", Pediatr Blood Cancer, 59, pp.854~858 (2012)[DOI]
- Schmitt T, "Gemcitabine and docetaxel for metastatic soft tissue sarcoma: a single center experience", Onkologie, 36, pp.415~420 (2013)
- Lee EM, "Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma", Cancer Chemother Pharmacol, 69, pp.635~642 (2012)[DOI]
- 이하영, "Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis", Cancer Research and Treatment, 44(1), pp.43~49 (2012), 대한암학회